Durability of Linear Small-Intestinal Growth Following Treatment Discontinuation of Long-Acting Glucagon-Like Peptide 2 (GLP-2) Analogues.

Tierah Hinchliffe Mirielle L PaulinePamela R WizzardPatrick N NationPatricia BrubakerJhenielle R CampbellYunji KimVioletta DimitriadouPaul W WalesJustine M Turner

Published in: JPEN. Journal of parenteral and enteral nutrition (2020)

Unlike mucosal adaptation, intestinal growth appears to be a lasting outcome of treatment with long-acting GLP-2 analogues in a neonatal piglet short-bowel model. This has significant clinical implications for neonates, given their potential for intestinal growth. Intestinal lengthening varies between analogues with different half-lives; however, molecular mechanisms require further elucidation.

Keyphrases

structure activity relationship
combination therapy
preterm infants
climate change
human health
replacement therapy